India's Pharma Industry: Investing For A Healthier Future

India's pharmaceutical industry is a significant global player, currently ranked third in pharmaceutical production by volume and 14th by value. The industry is projected to grow at a CAGR of over 10% to reach a size of $130 billion by 2030 and a $450 billion market by 2047. India has a well-established domestic pharmaceutical industry, featuring a network of around 3,000 drug companies and approximately 10,500 manufacturing units. The country is the largest provider of generic drugs globally, with a 20% share of total global pharmaceutical exports, and is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured. The Indian pharmaceutical sector provides several benefits for its investors, including cost-effective manufacturing, a large pool of scientific know-how, and economic growth. The government of India also supports the industry through effective policies and foreign investment laws.

India's pharmaceutical industry is the world's largest provider of generic drugs by volume

The Indian pharmaceutical sector has several advantages that ensure its prominent position in the global market. One of its key strengths is the ability to manufacture large quantities of low-cost generic medicines. This is possible due to the low cost of production, which is 30-35% lower than in the US and Europe, and cost-efficient R&D, which is about 87% cheaper than in developed markets. Additionally, India has a large pool of skilled labour, a strong scientific and technological base, and growing government support. These factors have established India as the "Pharmacy of the World", with its medicines preferred worldwide due to their low price and high quality.

The Indian pharmaceutical industry's generic drug manufacturing capabilities are exceptional. With over 500 API manufacturers, India contributes about 8% to the global API industry. The country produces more than 60,000 generic drugs across 60 therapeutic categories, accounting for a significant share of the global supply. This has made Indian pharmaceutical companies key players in the global market, with substantial shares in the prescription markets of the US and EU.

The success of India's pharmaceutical sector extends beyond generic drugs. The country is also the largest vaccine supplier in the world by volume, producing more than 60% of all vaccines and fulfilling 40-70% of the WHO's demand for essential vaccines such as DPT, BCG, and measles. India's role in providing affordable HIV treatment is also globally recognised, and its medicines are preferred for their quality and low cost.

The future of India's pharmaceutical industry looks promising, with a projected market value of US$130 billion by 2030. The government's initiatives, such as the Production Linked Incentive (PLI) Schemes, aim to further enhance India's manufacturing capabilities, boost domestic production, and attract investments. With its cost-effective manufacturing, skilled workforce, and strong domestic market, India's pharmaceutical industry is well-positioned for continued growth and global leadership.

India is a global leader in research and innovation, with a strong scientific and technological base

India's pharmaceutical sector has emerged as a global leader in research and innovation, driven by a robust scientific and technological base, growing government support, a strong domestic market, and cost-competitive manufacturing. The country has a well-established domestic pharmaceutical industry, with a network of around 3,000 drug companies and approximately 10,500 manufacturing units. The Indian pharmaceutical industry is currently ranked third in pharmaceutical production by volume and 14th by value.

The sector is characterised by a strong scientific and technological base, with India having the largest number of US-FDA-compliant pharmaceutical plants outside the US and over 2,000 WHO-GMP-approved facilities. This robust infrastructure enables the country to serve demand from 150+ countries worldwide.

The Indian pharmaceutical sector's leadership in research and innovation is also reflected in its role as the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. This dominance in the generic drugs market is a result of India's ability to manufacture bulk quantities of low-cost, high-quality medicines. The country's scientific and technological prowess is further demonstrated by its position as the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured globally.

The Indian government has played a pivotal role in supporting the pharmaceutical industry's growth and innovation. Various schemes and policies have been implemented to boost domestic manufacturing, enhance product diversification, and promote research and development. The government has also introduced favourable foreign investment laws, allowing up to 100% FDI in the pharmaceutical sector through the automatic route for greenfield projects.

The strength of India's pharmaceutical industry lies in its ability to combine a robust scientific and technological base with cost-effective manufacturing capabilities. This has positioned the country as a global leader in research and innovation, with a strong network of domestic companies driving the development of new medicines and treatments.

India is the largest vaccine supplier in the world by volume, accounting for over 60% of all vaccines manufactured

India's dominance in vaccine supply is underpinned by its ability to produce large quantities of low-cost generic medicines. This competitive advantage has been a key driver of the country's success in the pharmaceutical market. The country's strong scientific and technological base, coupled with growing government support and a large domestic market, have created favourable conditions for the industry's growth and innovation. The Indian government has also implemented various schemes and incentives, such as the Production Linked Incentive (PLI) Scheme, to boost domestic manufacturing and promote self-reliance in the pharmaceutical sector.

The significance of India's role in vaccine production is particularly evident in the supply of DPT, BCG, and measles vaccines. India contributes to 60% of global vaccine production, meeting up to 70% of the World Health Organization's (WHO) demand for DPT and BCG vaccines and fulfilling 90% of the demand for measles vaccines. This makes India an indispensable partner in global health initiatives and a reliable source of affordable and life-saving vaccines.

India's large-scale vaccine production has had a profound impact on global health outcomes. The country's ability to manufacture and distribute low-cost vaccines has improved access to essential immunisations for people worldwide, especially in low- and middle-income countries. India's contribution to global vaccine supply has been instrumental in controlling and preventing the spread of vaccine-preventable diseases, protecting vulnerable populations, and supporting international efforts to improve health outcomes on a global scale.

The country's robust vaccine manufacturing capabilities were further highlighted during the COVID-19 pandemic. India's capacity for mass vaccine production and distribution played a critical role in the global response to the pandemic. Through initiatives like the Vaccine Maitri programme, India supplied COVID-19 vaccines to numerous countries, demonstrating its commitment to global health cooperation and solidarity.

India's pharmaceutical industry is projected to grow at a CAGR of over 10% to reach a size of $130 billion by 2030

The Indian pharmaceutical industry's growth is supported by government policies and initiatives such as 'Pharma Vision 2020' and 'Make in India', with the aim to become a global pharmaceutical hub. The industry is expected to leverage robotics and digitalization, and the use of advanced technologies will play a crucial role in achieving its growth targets.

To sustain its growth trajectory, the Indian pharmaceutical industry must focus on innovation-led research and development, healthcare delivery, manufacturing, and supply chain enhancements, and improved market access. The industry has grown at a compounded annual growth rate (CAGR) of approximately 13% over two decades, and to reach the $130 billion target by 2030, it will need to double its growth rate from the previous decade.

The Indian pharmaceutical sector has emerged as a global leader in research and innovation, driven by a robust scientific and technological base, increasing government support, a strong domestic market, and cost-competitive manufacturing. The sector contributed nearly 1.32% of the Gross Value Added to the Indian Economy in 2020-21, with a total annual turnover of $42.34 billion in the fiscal year 2021-22.

The Indian pharmaceutical industry is well-positioned to maintain its leadership in the global market, with its strong scientific and technological capabilities, growing government support, and large domestic market. India's cost-competitive manufacturing capabilities also make it an attractive destination for global pharmaceutical companies seeking to conduct R&D and leverage the country's skilled workforce.

India has the largest number of USFDA-compliant pharmaceutical plants outside the US

The Indian pharmaceutical industry's compliance with USFDA standards is a testament to its commitment to producing high-quality, safe, and effective medicines. This recognition enhances India's reputation as a trusted supplier of pharmaceutical products and contributes to its position as the "pharmacy of the world." India's pharmaceutical sector is known for its low-cost manufacturing, efficient R&D, and skilled labour, making it a competitive player in the global market.

The presence of USFDA-compliant plants in India facilitates the production and supply of critical drugs and treatments, such as generic medicines and vaccines. India is the largest provider of generic medicines globally, with a 20% share in the global supply by volume. The country also accounts for 60% of global vaccine production and is a leading supplier of DPT, BCG, and measles vaccines. India's ability to produce and supply these life-saving medications is crucial in ensuring their accessibility and affordability worldwide.

Additionally, the large number of USFDA-compliant plants in India contributes to the country's economic growth and development. The pharmaceutical industry is a significant contributor to India's economy, with a total market size expected to reach US$130 billion by 2030 and US$450 billion by 2047. The sector provides employment opportunities and attracts foreign investment, further boosting India's economic landscape.

In conclusion, India's distinction of having the largest number of USFDA-compliant pharmaceutical plants outside the US reinforces its position as a global leader in the pharmaceutical industry. This achievement highlights India's ability to meet international standards, supply critical medications, and drive economic growth, ultimately benefiting people around the world who rely on affordable and high-quality pharmaceutical products.

Frequently asked questions